Mesothelioma Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center
|10-290-A||CALGB 30901 Randomized Phase II Study of
Maintenance Pemetrexed Versus Observation
for Patients with Malignant Pleural
Mesothelioma without Progression after
|IRB13-1268||Long-Term Follow-Up of Subjects who Have Participated in Aduro-Sponsored Protocols
|IRB12-2200||A Phase IB Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination with Pemetrexed and Cisplatin as Front-line Therapy in Adults with Malignant Pleural Mesothelioma
|IRB14-0592||Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination with Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway Signaling
|13473A||Utilization of Previously Banked Tissue from Patients with Lung Cancer, Mesothelioma, Thymoma/Thymic Carcinoma, and Esophageal Cancer and Correlation with Clinical Data.
|11-0755||The International Association for the Study of Lung Cancer IASLC Prospective Malignant Pleural Mesothelioma Staging Project
|9571||Tissue Procurement for Lung Cancer, Esophageal Cancer, Thymoma, and Mesothelioma in Patients Undergoing Surgery or Biopsy
|IRB14-1381||A Phase II study of the Anti-PD-1 Antibody
Pembrolizumab in Patients with Malignant
|IRB14-0081||Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team